Excellent point by Drano “this is the method. Spread a

New Post Public Reply Private Reply Replies (1) Message Board
Mo Drano #70053
1,269
Excellent point by Drano “this is the method. Spread a lie, get jumpy shareholders to sell, and then, if the clinical trial results are good, well, they were able to get rid of some shareholders who won't buy in again.”

Excellent point by 4kids “I never focus on the PPS, that is how NR (non retail) and CEs (colluding entities) prey on retail investors”

Let me attempt to tie these 2 important points together. Look at yesterday’s trading where a supposed 1.58M shares were traded within a 2 cent range and the opening share price (SP) and closing share price was not within a penny or even a tenth of a penny but exactly the same one hundredth of a penny at .3036. Anyone paying attention to this statistical impossibility knew that this was simply an in-your-face market manipulation. Then today’s trading with similar B.S. and around noon there were 560k shares traded with minimal SP movement. In the last couple hours or so “volume” spiked to end at 3.39M shares and SP got slammed by over 4 cents. IMO if there has been any news that has leaked (not from IPIX itself) it is most likely positive news and possibly stellar news. Why would SP go down on upcoming good news? Because the criminals (Non Retail or NR) control IPIX SP and they are significantly upside-down on IPIX.

There are numerous milestones that I believe IPIX will achieve in the next few months and I do not want to minimize any of them including:

- B-IBD UC Phase 2 projected start date
- Rutgers RBL Brilacidin inflammation PR and/or Preprint
- Detailed DoD presentation that was to be given at military symposium
- EUA for B-CV19 from US and/or other country
- B-CV19 Phase 3 initiation
- Development of inhaler and/or depo delivery for B-CV19
- Key additions to the IPIX BOD
- Up List off of the corrupt OTX

…….but there are 2 very key milestones that will allow the above to take place and catapult IPIX to success which in turn will have a huge long term impact on IPIX SP. These 2 milestones are:

1) Successful B-CV19 trial results.
2) Funding (grants and/or partnerships).

Once these 2 key milestones take place there is absolutely no chance for any entity to stop IPIX’s success. The B-CV19 database lock has most likely taken place and the unbinding and analysis of the trial data is most likely underway by the CRO. Hopefully the CRO will provide the finalized data to IPIX by the end of the month and Leo will PR Top Line Results in early September. This is not a prediction of a timeline. The point is that no one knows the trial result at this point. There could however be agreements being drafted that are contingent on positive trial results which is what most IPIX investors believe will successfully happen.

I have a large group of friends and family that have followed me into investing in IPIX. I have told them all the very same point that 4kids makes which is that IPIX is a milestone investment and IPIX short term SP does not matter. The criminals (NR) will continue to collude to compress IPIX SP until they are no longer able to. IMO the milestones of trial success and funding will put a stake in their heart. (I hate to use this graphic of an analogy but I can’t think of a better one to describe the blood-suckers losing control). There will be a full court press by the criminals between now and Top Line results in the next month or so. The criminals will continue to collude by juggling shares amongst themselves and will most likely continue to dig themselves yet a deeper NSS hole. The criminals will use every FUD tactic in their playbook to try to scare investors into selling and to try to minimize the upside once trial results are indeed successfully announced. The criminals need IPIX investors to sell shares under the $5 range. The criminals need IPIX to become a trading stock vs the current environment of stubborn investors holding tight as they know what they own. Once IPIX share price is over $5 there will be institutional demand for the small biotech that has the first and only Covid-killer. Leading up to this we will see IPIX daily volumes in the 10M+ range and eventually in the 30M+ range once institutional demand kicks in. Every dollar increase in IPIX SP will cost the criminals $300M-$500M. At some point in the future when volume is high enough there will be a massive short squeeze. This cannot take place IMO until institutional investor demand kicks in and volume is in the 20M+ range on a consistent daily basis. In the Short term I am expecting IPIX SP to continue to be artificially compressed and very volatile. The criminals will do their best to condition retail investors to trade and sell their IPIX positions. IMO the pendulum will start to swing after successful trial results and funding are announced. IMO the most significant gains in IPIX SP will take place the end of this year and throughout 2022.



Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Festo's CIP Safety Module: Impacting Pneumatic Systems

Updated Category News Views 33

Festo's Pneumatic Safety Game-Changer Festo is stirring up quite a fuss at the Automation Fair in Boston this year, and it's not just hot air. Their new CPX-AP-A CIP Safety module is a standout. This jolt of innovation is geared to revolutionize the way safety is approached in pneumatic systems. The key? Seamless integration and robust performance, not to mention a...

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 83

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 77

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
O-I Glass Faces Class Action: What Investors Must Know

Updated Category News Views 85

The Unsettling News for O-I Glass Investors Let me dive right into this mess about O-I Glass, Inc. (NYSE:OI). If you're tangled up in their stock, you probably felt that 15.01% nosedive in your portfolio recently. That's no minor blip. On July 28, 2026, as stocks were virtually put through the shredder, O-I Glass announced they had to cut down their financial guidance for...

Continue Reading
Understanding Cataracts: What Investors Should Know

Updated Category News Views 130

The Subtle Slowdown in Vision When it comes to cataracts, things don't just suddenly hit you like a ton of bricks. It’s a slow burn—cataracts develop over months or even years. Your vision starts feeling like it’s giving up on high definition. The lens in your eye starts to get cloudy, like a fog rolling in on a morning drive. You're not going to wake up one day...

Continue Reading
Replit Wins 2026 Microsoft Startup Partner Award

Updated Category News Views 51

Replit's Triumph in the Microsoft Ecosystem If there's one thing you come to expect from this dizzying dance of technology and business, it's that standout players get their due when they push the envelope. Replit just snagged a gleaming accolade by being named Microsoft's 2026 Partner of the Year for Startups. That's a hefty badge, especially coming from a giant like...

Continue Reading
Nicklaus and Horvat Honored by Palm Beach Atlantic

Updated Category News Views 131

The Spirit of Golf Meets Enterprise Well, folks, Palm Beach Atlantic University is rolling out the red carpet for two very different, yet equally successful figures in the world of golf. On November 17, their 42nd annual American Free Enterprise Day will recognize Jack Nicklaus, the indomitable Golden Bear, and Grant Horvat, a fresh face and driving force in the golf...

Continue Reading
Water Wings Swim School Splashes into Billings

Updated Category News Views 92

Billings Dives into the Swim School Scene Well, folks, Billings is about to get its feet wet with something new and well-needed in the local scene. Come November 21, Montana will welcome its first dedicated swim school as Water Wings opens shop right here in Billings at 2618 King Ave W. This ain't just run-of-the-mill comic relief on disaster-preparedness. We're talking...

Continue Reading
QFIN Lawsuit: Executives Face Control Liability

Updated Category News Views 82

QFIN Executives in Legal Hot Water Qfin Holdings, Inc. (NASDAQ: QFIN) is in a tight spot as a securities class action lawsuit casts a harsh spotlight on its senior executives. The CEO and CFO, during the contested class period, are front and center in this legal tangle. Qfin's stockholders are grappling with losses, and it's all tied back to some certified SEC filings...

Continue Reading
Elypta's Urine Biomarker Study: Breakthrough in Cancer Risk

Updated Category News Views 98

What's Going on with Elypta? Well, isn't this an intriguing twist in cancer risk prediction? A Swedish company, Elypta, just tossed its hat into the medicinal ring with some fascinating findings. They're leveraging a study that analyzes urine biomarkers to predict cancer risk over a five-year span. Tackling a whopping cohort of 5,436 adults, it's as ambitious as it...

Continue Reading

Top 5 Most Recently Viewed Articles

Fortune Bay's Goldfields Project: A Bright Future Ahead

Updated Category News Views 180

Overview of Goldfields' Updated PEA Fortune Bay Corp. is making waves in the mining industry with its recently updated Preliminary Economic Assessment (PEA) for the Goldfields Gold Project. This project, fully owned by Fortune Bay, is set to unlock tremendous value through its expansive gold resources and strategic approach to mining operations. Highlights of the Updated...

Continue Reading
Crypto and EV Market Changes Impact Investors Amid New Trends

Updated Category News Views 118

Turbulent Times for Cryptocurrency In recent days, the cryptocurrency market has witnessed a significant downturn, with major players like Bitcoin, Ethereum, and Dogecoin facing declines. These changes are heavily influenced by looming fears regarding sell-offs from government-held crypto assets. Analysts suggest that this uncertainty could lead to increased volatility in...

Continue Reading
Ford Supports Hispanic Youth Soccer with Grants Program

Updated Category News Views 110

Ford and Alianza de Futbol Collaborate for Youth Empowerment In an inspiring move for young athletes, Ford Motor Company has partnered once again with Alianza de Futbol to enhance opportunities for Hispanic youth soccer players. Now in its second year, the Ford Qué Golazo de Grants program aims to provide essential support for aspiring players, creating pathways to...

Continue Reading
Transforming Your Investment: The Viking Therapeutics Journey

Updated Category News Views 321

Investing in Viking Therapeutics: A Success Story Viking Therapeutics (NASDAQ: VKTX) has seen remarkable growth over the past five years, significantly exceeding market expectations. The company has achieved an astounding annualized return of 55.96%, outperforming the market by 41.66%. Currently, its market capitalization stands at an impressive $6.91 billion, signaling...

Continue Reading
Petrus Resources Enhances Shareholder Value with NCIB Renewal

Updated Category News Views 129

Petrus Resources Signals Growth with NCIB Renewal Petrus Resources Ltd. is excited to announce a significant milestone for the company and its shareholders. Recently, the Toronto Stock Exchange (TSX) accepted Petrus' intention to renew its normal course issuer bid (NCIB), aimed at purchasing up to 6,448,237 common shares—accounting for 5% of its outstanding shares. This...

Continue Reading